SOAT1 and pulmonary fibrosis: Although clinical data are limited, preclinical studies have demonstrated that baricitinib attenuates lung fibrosis in mouse models by inhibiting the JAK/STAT and TGF-β signaling pathways (Gu et al., 2023).